Inhibiting Factors and Promotion Strategies to the Implementation of HPV Vaccination Provision in our Country: Analysis Based on the Smith Model_Vol. 1 No. 3 (JMSD 2024)_Journal of Management and Social Development (ISSN: 3005-5741)

Home > Journal of Management and Social Development (ISSN: 3005-5741) > Vol. 1 No. 3 (JMSD 2024) >

Inhibiting Factors and Promotion Strategies to the Implementation of HPV Vaccination Provision in our Country: Analysis Based on the Smith Model

Download PDF

DOI: https://doi.org/10.62517/jmsd.202412346

Author(s)

Jiayi Xin, Hangqi Xie*

Affiliation(s)

School of Law and Humanities, China University of Mining and Technology-Beijing, Beijing, China *Corresponding Author.

Abstract

In recent years, the incidence rate of cervical cancer has continued to rise and shows a trend towards younger individuals, making cervical cancer prevention and control an important aspect of safeguarding public health. HPV vaccination significantly reduces the incidence of cervical cancer, highlighting the crucial importance of promoting HPV vaccination among eligible women. Currently, the implementation of HPV vaccination provisions remains imperfect. To further increase vaccination rates and maximize the benefits of HPV vaccination, this study, based on the Smith model, analyzes the inhibiting factors in provision implementation from four aspects: idealized provision, provision implementation entities, target population, and provision implementation environment. Based on this analysis, the study proposes generalizable suggestions and recommendations to contribute to advancing HPV vaccination and cervical cancer prevention and control efforts.

Keywords

HPV Vaccination; Implementation of HPV; Smith Model; Inhibiting Factors; Promotion Strategies

References

[1] Tian Guoliang, HAO Yuxin, WANG Jiwei. Research status and vaccination policy of human papillomavirus vaccine. Shanghai Preventive Medicine:1-16[2024-03-09]. [2] Hu Yuexia, Xia Xin, Tian Xin, et al. Analysis of the correlation between the vaccination situation and the critical type in hospitalized patients infected with Omicron variant of novel coronavirus. Chinese Journal of Evidence-Based Medicine, 2019, 24(03):258-264. [3] Yang Na. Popularize HPV vaccination, let women completely bid farewell to cervical cancer. China Women's News, 2021-12-01(008). [4] Chen Yaxi, Sudan. Research progress on human papillomavirus vaccination intention, vaccination rate and influencing factors among female college students in China. School health in China:1-5[2024-03-11]. [5] Shi Yajia, WANG Hongyan, Zhang Ling et al. Investigation on current cognition of HPV and its vaccine among college students in North China Modern PreventiveMedicine, 2021, 48(04):727-731. [6] Meng Fanli, Song Fengbin, Ye Jiayao et al. Human papillomavirus and vaccine cognition and vaccination intention of Hangzhou female University students . Chinese School Health, 2020, 41(11):1737-1741. [7] Zheng Hao, SHEN Fangning, ZHANG Yeni et al. HPV vaccine awareness and vaccination intention of women's College students in Zhejiang Province . Journal of Huzhou Teachers College, 2021, 43(10):74-80. [8] Xiao Ling, HUANG Guangmei, Zhang Xueli et al. Investigation and analysis on cognition of cervical cancer prevention and control and intention of HPV vaccination among college students in Xiangyang City . Public health and preventive medicine, 2022, 33(03):104-108. [9] Wu Simin. 13 Departments issued a document to promote HPV vaccination industry suggested to optimize vaccination policy. China Business News, 2023-11-17(A02). [10] Zheng Wenxin, Ye Yu, Xu Weijie et al. A review of human papillomavirus vaccination in rural women . Chinese Rural Health, 2022, 14(11):70-72. [11] Jiao Yanhui, XIA Xueqin, Hu Weijun. Analysis of HPV vaccination in the prevention clinic of Shaanxi Provincial Center for Disease Control and Prevention . Public health and preventive medicine, 2022, 33(1) :132-135. [12] Zhang Mengling, Liang Jiangming, Liang Fuxiong, et al. Application and development of HPV vaccine . Internal medicine, 2020, 15( 3) :307-311. [13] Szarewski A. Cervarix: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Review of Vaccines, 2012, 11(6):645-657. [14] Vandamme P, Meijercjlm, Kieningerd, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men . Vaccine, 2016, 34(35):4205-4212.